Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.


Journal Article

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Full Text

Cited Authors

  • Jankovic, J; Hunter, C; Dolimbek, BZ; Dolimbek, GS; Adler, CH; Brashear, A; Comella, CL; Gordon, M; Riley, DE; Sethi, K; Singer, C; Stacy, M; Tarsy, D; Atassi, MZ

Published Date

  • December 2006

Published In

Volume / Issue

  • 67 / 12

Start / End Page

  • 2233 - 2235

PubMed ID

  • 17190952

Pubmed Central ID

  • 17190952

Electronic International Standard Serial Number (EISSN)

  • 1526-632X

International Standard Serial Number (ISSN)

  • 0028-3878

Digital Object Identifier (DOI)

  • 10.1212/01.wnl.0000249308.66959.43


  • eng